Does STEM Cell Therapy Work for Arthritis?
Stem cell therapy can work for arthritis, particularly in knee osteoarthritis where the strongest research evidence exists, with growing data for the hip and shoulder. Results vary by joint, severity, and protocol, and the therapy is not FDA-approved for any arthritis indication. Evidence for rheumatoid arthritis remains more limited than for osteoarthritis.
What the Evidence Shows for Stem Cell Therapy for Arthritis
- Knee osteoarthritis: strongest evidence base; multiple randomized trials show pain reduction and improved function
- Hip osteoarthritis: smaller body of clinical research; encouraging early outcomes
- Shoulder osteoarthritis: emerging evidence base, with fewer published trials
- Rheumatoid arthritis: research focuses on immune modulation; evidence remains earlier and smaller
- FDA status: not approved for any arthritis indication in the United States
- Variation: outcomes depend on joint, severity, cell source, and clinic protocol
How Stem Cell Therapy Is Used to Treat Arthritis
Stem cell therapy for arthritis typically involves an injection into the affected joint to reduce inflammation and support tissue repair at the source of joint damage. The most studied approach uses mesenchymal stem cells (MSCs), drawn from the patient’s own bone marrow, fat tissue, or blood, or from donor sources such as umbilical cord tissue. MSCs have anti-inflammatory and immune-modulating properties.
Two distinct conditions sit under the term “arthritis.” Osteoarthritis is the wear-and-tear form, where cartilage between bones breaks down over time. Rheumatoid arthritis is autoimmune, with the immune system attacking joint tissue. The therapeutic target varies for each condition, and research into stem cell therapy for arthritis follows separate tracks for each.
What the Research Shows for Knee Osteoarthritis
Knee osteoarthritis has the most developed evidence base. A 2024 meta-analysis of 18 randomized controlled trials found that mesenchymal stem cell injections reduced pain and improved joint function at 12-month follow-up compared with placebo or other non-surgical approaches. More recently, a 2026 meta-analysis of 11 RCTs reported significant pain and functional improvements that grew over time, with the largest benefits at 24 months. Studies vary in cell source, dose, and patient selection, and most participants have early to moderate disease rather than advanced “bone-on-bone” arthritis. Adverse events were uncommon across reviewed trials.
Hip and Shoulder Osteoarthritis: A Smaller Evidence Base for Stem Cell Therapy
The research base for stem cell therapy is smaller for the hip and shoulder than for the knee.
A 2025 scoping review of stem cell therapy for hip osteoarthritis identified nine clinical studies, with most being cohort and case series. Most reported pain reduction and functional improvement, but no large randomized trials for hip OA have yet been published. Shoulder osteoarthritis has even less published research, with most data coming from small case series and early-stage trials.
This matters for research-stage decisions. Anyone considering stem cell therapy for hip arthritis is working with less mature data than for the knee. The same is true for stem cell therapy for shoulder arthritis. Early signals are encouraging. Conclusions cannot yet be drawn with the same confidence as for the knee.
Rheumatoid Arthritis: A Different Therapeutic Target for Stem Cell Therapy
Rheumatoid arthritis is an autoimmune condition, and stem cell therapy approaches it differently than osteoarthritis. The aim is immune modulation rather than cartilage repair.
A 2023 systematic review and meta-analysis reported a favorable safety profile for mesenchymal stem cell therapy in rheumatoid arthritis patients, along with a trend toward improvement that the authors said still needs confirmation in larger, higher-quality studies. The takeaway for RA is that the research is earlier in development, the trials are smaller, and the standard of care still centers on disease-modifying medications managed by a rheumatologist. Stem cell therapy here is best understood as an investigational option.
FDA Status of Stem Cell Therapy for Arthritis in the United States
Stem cell therapy is not FDA-approved for any orthopedic condition, including arthritis.
According to the FDA’s consumer information page, regenerative medicine therapies have not been approved for osteoarthritis, tendonitis, disc disease, or other orthopedic conditions. The only FDA-approved stem cell products in the United States come from umbilical cord blood. They are used for certain blood disorders.
Stem cell treatments for arthritis are typically offered as investigational therapies outside FDA-authorized clinical trial pathways. The FDA encourages patients to ask whether the specific therapy is part of an active clinical trial with an Investigational New Drug (IND) authorization. Patients considering stem cell therapy for arthritis should verify the regulatory status of the specific product, who is providing it, and what evidence supports its use for the joint and condition involved.
Questions to Ask Before Considering Stem Cell Therapy for Arthritis Treatment
If you are considering stem cell therapy for arthritis, the questions below help separate well-evidenced practice from marketing claims.
- Where do the cells come from? Drawn from your own body (bone marrow, fat, or blood), or from a donor source such as umbilical cord tissue?
- Is the therapy part of an FDA-authorized clinical trial with an IND number?
- What outcomes does the clinic report for your specific joint and condition, and can they provide peer-reviewed evidence for the exact product they offer?
- Who performs the procedure, and what are their credentials in regenerative medicine?
- What is the realistic expected outcome, and how is it measured (pain scale, functional score, imaging)?
- What is the recovery and follow-up plan, and how does the clinic handle complications?
Frequently Asked Questions About Stem Cell Therapy for Arthritis
How long does stem cell therapy take to work for arthritis?
Most patients in clinical trials begin to notice changes in pain or function between 6 and 12 weeks, with continued improvement over 6 to 12 months. Long-term studies report the largest effects at 24 months, though individual response varies based on cell source, disease severity, and joint.
Is stem cell therapy a substitute for joint replacement surgery?
Is stem cell therapy a substitute for joint replacement surgery?
For most patients with advanced “bone-on-bone” osteoarthritis, joint replacement remains the established treatment with the strongest evidence record. Stem cell therapy is more often considered for patients with mild to moderate arthritis or those looking to delay surgery. The decision should be made with an orthopedic specialist.
How much does stem cell therapy for arthritis cost?
Stem cell injections for arthritis are generally not covered by insurance and are paid out of pocket. Reported pricing in the orthopedic literature varies widely, with many clinics charging between $3,000 and $10,000 per joint. Some clinics sell multi-treatment packages, and high cost is not a measure of quality or stronger evidence.
Are stem cells from your own body safer than donor stem cells?
Cells drawn from your own body may reduce certain immune compatibility concerns because the material comes from the same person being treated. Some safety concerns specific to donor-derived products, including amniotic and umbilical cord preparations, have been raised by the FDA. No injection is fully risk-free, and source is only one factor affecting safety.
How Quantum VSEL Approaches Stem Cell Therapy for Arthritis
This page raises questions about cell source, evidence, FDA status, and who is performing the procedure. Quantum VSEL Stem Cell Therapy in Tampa, Florida is built around the same questions. The therapy uses Very Small Embryonic-Like (VSEL) cells drawn from the patient’s own blood, with no donor material, umbilical cord preparations, or amniotic products involved.
VSEL cells are already present in your blood and remain dormant unless activated. That activation comes from the SONG laser. It is a proprietary cold laser technology developed by Dr. Todd Ovokaitys to wake up these dormant cells before they are reintroduced.
Quantum VSEL is a Tampa-based practice. Oksana Su personally performs each procedure, candidacy is evaluated up front, and follow-up care is built into every plan.
For someone evaluating stem cell therapy for arthritis, the practical questions are the same ones outlined above: where the material comes from, the practitioner’s role, realistic outcomes, and aftercare. We are happy to walk through any of those in detail.
To learn more or ask a question about how stem cell therapy for arthritis may fit your situation, contact us at info@vselstem.com or call 813-682-7033.
Related Topics:
If you are researching your options, the guides below cover related questions about stem cell therapy and what to consider before treatment.
